Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2017-03-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于公司发行股份购买资产暨关联交易之补充独立财务顾问报告（一）
Capital/Financing Update Classification · 95% confidence The document is titled as a "Supplementary Independent Financial Advisor Report (I)" related to 嘉事堂药业股份有限公司's issuance of shares to purchase assets and related party transactions. It references regulatory feedback from the China Securities Regulatory Commission (CSRC) and discusses detailed financial, legal, and operational due diligence on a major asset acquisition and restructuring transaction. The content includes detailed analysis of transaction pricing, asset control, legal compliance, financial evaluations, and risk assessments. This type of document is a specialized financial advisory report prepared for a major asset restructuring and share issuance transaction, which aligns with the category of Capital/Financing Update (CAP) filings. It is not a full annual or interim report, audit report, or earnings release, but a detailed advisory report on a capital transaction and related asset purchase. Therefore, the appropriate classification is CAP with high confidence.
2017-03-30 Chinese
发行股份购买资产暨关联交易报告书（修订稿）
Regulatory Filings
2017-03-30 Chinese
中联资产评估集团有限公司关于公司拟购买北京嘉事盛世医疗器械有限公司等12家公司少数股权所涉及的12家公司股东全部权益评估项目复核报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation review report by Zhonglian Asset Appraisal Group Co., Ltd. for Jiashitang Pharmaceutical Co., Ltd.'s proposed purchase of minority equity interests in 12 companies. It includes extensive financial data, asset and liability details, valuation methods, assumptions, and summaries of the companies' business and financial conditions as of the valuation date (September 30, 2016). The document is not an announcement or a brief summary but a comprehensive appraisal report with substantive financial data and analysis. It is related to an asset valuation for a transaction, which aligns with an Audit Report / Information (AR) category, as it is a standalone valuation and review report supporting a transaction but not a full annual or interim financial report. Therefore, the appropriate classification is AR with high confidence. 9M 2016
2017-03-30 Chinese
立信会计师事务所（特殊普通合伙）关于收到中国证券监督管理委员会及派出机构执业质量监管措施的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special inspection opinion from an accounting firm (立信会计师事务所) regarding regulatory disciplinary actions, investigations, and administrative supervision measures received from the China Securities Regulatory Commission (CSRC) and its local offices. It includes summaries of administrative penalties, ongoing investigations, and regulatory measures related to the firm's audit work for various companies. The document specifically addresses the firm's qualifications and the impact of these regulatory issues on the audit quality for a particular transaction (嘉事堂药业股份有限公司发行股份购买资产暨关联交易). The content is focused on audit quality, regulatory compliance, and the firm's status rather than presenting financial statements or audit results themselves. It is not an annual report, audit report of a company, or financial statement. Instead, it is a standalone audit-related regulatory disclosure about the audit firm itself and its regulatory history. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document length (4268 characters) is sufficient to be the report itself, not just an announcement. Therefore, the classification is AR with high confidence. Q1 2017
2017-03-30 Chinese
北京市金杜律师事务所关于公司发行股份购买资产暨关联交易项目签字资产评估师变更的专项核查法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm (北京市金杜律师事务所) regarding a significant asset purchase transaction by 嘉事堂药业股份有限公司. It specifically addresses the change of signing asset appraisers related to the issuance of shares to purchase assets and related party transactions. The document references relevant Chinese laws and regulations, asset appraisal reports, and internal review reports. It is a specialized legal opinion focusing on the legality and compliance of the asset appraisal and the transaction process, rather than a financial report, earnings release, or general regulatory announcement. It does not contain financial statements or earnings data, nor is it a shareholder meeting material or voting result. It is not a certification or a brief announcement but a detailed legal opinion on a specific transaction. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for filings that do not neatly fit into other categories and includes legal opinions related to corporate transactions and compliance.
2017-03-30 Chinese
华泰联合证券有限责任公司关于公司发行股份购买资产暨关联交易项目评估复核报告及变更签字评估师的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a specialized verification opinion report issued by Huatai United Securities Co., Ltd. regarding the asset purchase by Jia Shi Tang Pharmaceutical Co., Ltd. through share issuance, involving related party transactions and the reassignment of signing asset appraisers. It references multiple asset appraisal reports for various companies and discusses the qualifications and legal responsibilities of the appraisers. The document is an independent financial advisor's special verification opinion on the appraisal reports and related changes, not the appraisal reports themselves or a general financial report. It is a regulatory disclosure related to a capital transaction and compliance with regulatory requirements, but it is not a full capital/financing update or a merger/acquisition filing. Given the nature of the document as a special verification opinion on appraisal reports and changes in signing appraisers, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is 3450 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2017-03-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.